Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Abstract Immune checkpoint blockade (ICB) therapies, which potentiate the body’s natural immune response against tumor cells, have shown immense promise in the treatment of various cancers. Currently, tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are the primary biom...

Full description

Bibliographic Details
Main Authors: Jake R. Conway, Eric Kofman, Shirley S. Mo, Haitham Elmarakeby, Eliezer Van Allen
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Genome Medicine
Subjects:
Biomarkers
Cancer
Checkpoint
CTLA-4
Genomic
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13073-018-0605-7

Internet

http://link.springer.com/article/10.1186/s13073-018-0605-7

Similar Items